Staging of primary cervical cancers: the role of nuclear medicine; Kridelka, Frédéric ; Thille, Alain et alin Critical Reviews in Oncology/Hematology (2003), 46(3), 275-284 In nuclear medicine, [F-18]-fluorodeoxyglucose positron emission tomography ((18)FDG PET) and lymphatic mapping and sentinel lymphadenectomy (LM/SL) may significantly improve the staging of primary ... [more ▼] In nuclear medicine, [F-18]-fluorodeoxyglucose positron emission tomography ((18)FDG PET) and lymphatic mapping and sentinel lymphadenectomy (LM/SL) may significantly improve the staging of primary cervical cancers. Indeed, the disease progresses in a 'level by level' fashion to regional nodes through the lymphatic channels, and also to extra-nodal sites via the hematogenous stream. Additionally, the sub-optimal efficacy of routine radiological protocols, while new combined therapies are proving to be more efficient, stresses the need for alternative staging procedures. Current data suggest that LM/SL accurately reflects the regional lymph node status in early stage cervical cancers, and thus could avoid unnecessary complete lymphadenectomies. Also, whole body (18)FDG PET may provide valuable insights on extra-pelvic and distant tumor spreading, with a significant impact on treatment choices. If these promising results are confirmed on large controlled trials, LM/SL and (18)FDG PET imaging could be incorporated in the routine staging work-up of primary cervical cancers. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved. [less ▲] Detailed reference viewed: 16 (2 ULg) Oncological Applications of Positron Emission Tomography with Fluorine-18 FluorodeoxyglucoseRigo, Pierre ; ; et alin European Journal of Nuclear Medicine (1996), 23(12), 1641-74 Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical ... [more ▼] Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and follow-up. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved. [less ▲] Detailed reference viewed: 35 (1 ULg) |
||